Short answer
NovoCure Ltd (NVCR) filed its fiscal 2025 10-K annual report with the SEC on Feb 26, 2026. It reported revenue of $655M (+8.3% year over year) and net income of −$136M.
- Top risk flagged: FDA PMA approval dependency for Optune Gio sales; majority revenue from newly diagnosed and recurrent GBM indications
FY2025 key financial metrics · XBRL
- Revenue
- $655M
- +8.3% YoY
- Net income
- −$136M
- +19.2% YoY
- Operating margin
- -23.5%
- +4.7 pp YoY
- Gross margin
- 74.5%
- −2.8 pp YoY
- EPS (diluted)
- −$1.22
- +21.8% YoY
- ROE
- -40.0%
- +6.8 pp YoY
- Operating cash flow
- −$49M
- −85.9% YoY
Source: XBRL data from the NovoCure Ltd (NVCR) FY2025 10-K on SEC EDGAR. USD.
NovoCure Ltd FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: Commercialization of TTFields therapy devices (Optune Gio, Lua, Pax) delivering electric fields to kill cancer cells for solid tumor cancers
- New emphasis on brain metastases from NSCLC with September 2025 Phase 3 METIS trial showing 28% lower risk of intracranial progression; Optune Mya PMA submitted, FDA review ongoing
- Strategic expansion to pancreatic cancer with 2026 FDA approval of Optune Pax based on PANOVA-3 trial; survival improved to 16.2 vs 14.2 months (p=0.039)
- Sales force grew to 217 globally as of December 2025; estimated 8,200 GBM, 30,000 NSCLC, 15,000 pancreatic cancer patients in U.S. eligible and seeking treatment in 2026
- Unusual milestone: simultaneous regulatory progress with multiple devices; PMA filing acceptance for brain metastases (Optune Mya) and first U.S. approval for pancreatic cancer device Optune Pax
Management Discussion & Analysis
- Revenue and profitability details not provided in the provided MD&A excerpt
- Cash flow, capital allocation, and buybacks or dividends details absent
- Forward-looking guidance or emerging risks not mentioned in the excerpt
Risk Factors
- FDA PMA approval dependency for Optune Gio sales; majority revenue from newly diagnosed and recurrent GBM indications
- Geopolitical risk from Greater China market reliance on Zai partnership for development and commercialization
- Production dependency on third-party manufacturers for sufficient quality and quantity of Products
- Competition risk from alternative therapies impacting market acceptance despite FDA and CE approvals
- Historical substantial operating losses with intermittent profits; ongoing high commercialization and R&D expenses
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.